tailieunhanh - Insights into the current management of dyslipidemia from a clinical pharmacological perspective

The low-density lipoprotein cholesterol (LDL-C) is established as a causative agent of atherosclerotic cardiovascular disease (ASCVD) and lowering plasma LDL-C levels represents the main approach to reduce the risk of cardiovascular events. Statins remain the cornerstone of drug therapy for dyslipidemia. |

TÀI LIỆU MỚI ĐĂNG